Yorktown Management & Research Company’s Ultragenyx Pharmaceutical RARE Stock Holding History

Yorktown Management & Research Company’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$359K	Buy	+10,750	New	+$267K	0.22%	178

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EHI

Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return

Walleye Capital New York $28B AUM 44.22% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Yorktown Management & Research Company's RARE Position: Q2 2026 in Review

Yorktown Management & Research Company opened a new position in Ultragenyx Pharmaceutical (RARE) in Q2 2026: 10,750 shares worth $359K. The stake represents 0.22% of the portfolio and ranks #178 among its holdings.

111 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Yorktown Management & Research Company held 10,750 shares of Ultragenyx Pharmaceutical worth $359K as of Q2 2026.
Ultragenyx Pharmaceutical was a new Yorktown Management & Research Company position in Q2 2026.
Ultragenyx Pharmaceutical made up 0.22% of Yorktown Management & Research Company's portfolio in Q2 2026, its #178 holding.
111 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Yorktown Management & Research Company's 13F filing for Q2 2026, filed 23 Jul 2026.